Developer docs
API playgroundTry for free, no card

Search company profiles

Vivolta

Full company profile

uuid0000w5r

Namestring
Vivolta
Legal namestring
Vivolta B.V.
Websiteurl
vivolta.com
Company typeenum
Private
Founded yearint
2008
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaalre, Netherlands
HQ citystring
Waalre
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device manufacturing, electrospinning technology, contract development manufacturing, biomedical contract services, regenerative medical devices
Industry1 code
PRIMARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Medical Device Contract Manufacturing
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Development and Manufacturing (CDMO)
TypeProfessional Services
Description

VIVOLTA provides full-suite CDMO services spanning from concept development to commercial manufacturing. Services include feasibility testing, product & process development, process validation & scale-up, and clinical & commercial manufacturing. The company consolidates clients' supply chains into a one-stop-shop for electrospun medical products and components, managing raw material vendors and integrating post-processes such as laser cutting, packaging, and labelling.

vivolta.com
2Electrospinning Equipment Sales
TypeHardware Sales
Description

VIVOLTA sells EC-CLI climate-controlled electrospinning R&D platforms to academic research institutes and companies globally. Over 120 IME electrospinning R&D platforms have been sold and distributed across six continents.

vivolta.com
3Development Services
TypeProfessional Services
Description

Concept creation, feasibility testing, and product & process development services for medical device companies developing electrospun products.

vivolta.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vivolta is a fully integrated contract development and manufacturing organization (CDMO) that develops, validates, and manufactures electrospun medical products and components on its proprietary MediSpin™ automated production platform. Its services span concept creation, feasibility testing, product and process development, process validation and scale-up, and clinical and commercial manufacturing for cardiovascular, orthopaedic, wound care, drug delivery, dental, neurosurgery, and ENT applications. The company also sells EC-CLI climate-controlled electrospinning R&D systems to academic and corporate research users worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Fiber diameter deviation below 5% year-round with climate-sealed chambers holding ±0.5°C and ±1% relative humidity
+4 more records
Product overview1 text field

VIVOLTA is a fully integrated contract development and manufacturing organization (CDMO) specializing in electrospinning for the medical device industry. The company offers the MediSpin™ Platform as its core production technology—the world's first fully automated medical electrospinning production system—and the EC-CLI Platform for R&D purposes. VIVOLTA provides a full suite of CDMO services spanning from concept development to commercial manufacturing, including add-on modules for the EC-CLI such as the EM-ASM Anti-Statics Module, EM-GSM Gas Shield Module, EM-TMM Thickness Measurement Module, EM-RDC Rotating Drum Collector, and EM-CAX Coaxial Nozzle. The company manufactures various electrospun medical products and components for applications including cardiovascular, orthopaedic, wound healing, and drug delivery.

Product and service6 records
1MediSpin™ Production Platform
CategoryContract Manufacturing Platform
Description

The world's first and only fully automated, scalable medical electrospinning production platform, used by Vivolta to manufacture electrospun medical products and components at commercial scale with real-time sensor-controlled parameters and 100% in-line quality verification.

2EC-CLI Electrospinning R&D System
CategoryCapital Equipment
Description

Climate-controlled electrospinning R&D system with ±0.5°C and ±2% RH accuracy and modular plug-and-play add-ons, sold to academic and corporate research users globally for reproducible prototyping and process development.

3Contract Development Services
CategoryContract Development Services
Description

Full-service CDMO development offerings including concept creation, feasibility testing, and product and process development for medical device companies targeting electrospun implants and regenerative products.

4Contract Manufacturing Services
CategoryContract Manufacturing Services
Description

Clinical and commercial production services for electrospun medical products including process validation, scale-up, supply chain management, and integration of post-processes such as laser cutting, packaging, and labelling.

5SimplySilk® Membrane Manufacturing
CategoryContract Manufacturing Services
Description

Exclusive contract manufacturing of Fibrothelium's CE-marked Class III SimplySilk® resorbable barrier membrane for guided bone regeneration in dental implants, periodontal procedures, and cranio-maxillo-facial surgery, produced on MediSpin™ at commercial scale.

6Neurochase Micro-Catheter Manufacturing
CategoryContract Manufacturing Services
Description

Exclusive component manufacturing of Neurochase's electrospun micro-catheters for delivering advanced CNS therapies to the brain via convection enhanced delivery (CED), using MediSpin™ at scale.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-07
Description

VIVOLTA signed a long-term partnership with Fibrothelium, a specialist in silk protein biomaterials, to exclusively manufacture electrospun components for Fibrothelium's SimplySilk® membrane - an advanced electrospun silk membrane for guided bone regeneration (GBR) in oral surgery. VIVOLTA leverages its fully automated MediSpin™ technology to produce the electrospun membranes at commercial scale while ensuring consistent quality and regulatory compliance. SimplySilk® membrane is a CE-marked Class III medical device commercially available in Europe, with FDA submission targeted for 2027.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-14
Description

VIVOLTA signed a long-term partnership with Neurochase, a CNS delivery platform specialist, to manufacture electrospun micro-catheters for delivering advanced therapies to the brain via Convection Enhanced Delivery (CED). VIVOLTA first partnered with Neurochase in 2022 and has worked as part of Neurochase's R&D team, bringing material science and application development expertise. VIVOLTA will be Neurochase's exclusive component manufacturer based on its ability to manufacture electrospun medical products at scale using MediSpin™. Neurochase plans clinical trials in 2025.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

VIVOLTA, Avelo, and BLINK consortium awarded €1.5M Eurostars grant (BreathCounts project) to develop a diagnostic system for lower respiratory tract infections. VIVOLTA contributes electrospun filter technology for a disposable breath collection device. The project aims for market launch in 2027 with the world's first breath-based system for fast, accurate diagnosis of LRTIs.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

VIVOLTA, Avelo, and BLINK consortium awarded €1.5M Eurostars grant (BreathCounts project) to develop diagnostic system for lower respiratory tract infections using breath analysis technology combined with VIVOLTA's electrospun filter.

5Dutch Research Council (NWO)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-12-20
Description

VIVOLTA awarded NWO grant along with collaborators Delft University, DSM, and Meatable for Project SUSTAINER investigating feasibility of electrospinning natural and synthetic structural proteins for sustainable food and biomedical applications. Grant of €1 million as part of NWO's Open Technology Programme, running for five years.

vivolta.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-07-08
Description

VIVOLTA, STENTiT, and Corbion announced collaboration to develop an electrospun, regenerative stent for clinical use, initially focused on treatment of patients suffering from critical limb ischemia. The consortium aims to manufacture batches of clinical-grade stents together. The regenerative stent uses bioresorbable nanofibers that allow influx of circulating blood cells, triggering natural healing response for vascular regeneration, then safely resorbs over time.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-07-08
Description

VIVOLTA, STENTiT, and Corbion collaboration to develop regenerative stent for critical limb ischemia treatment. Corbion provides bioresorbable materials expertise as part of the Dutch Smart BioMaterials Consortium (SBMC).

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Dutch regenerative medicine company developing bioresorbable medical devices including dural and nerve repair products. Comparable electrospun/biopolymer device focus; Rudy Mareel (VIVOLTA Chairman) previously led Polyganics to its Regenity acquisition.

TypeEmerging player
Description

Israel-based regenerative medicine company using plant-derived recombinant human collagen for tissue repair and 3D bioprinting. Comparable in ECM-mimicking biomaterials for soft tissue, orthopaedic, and wound healing applications.

TypeBroad incumbent
Description

Dutch biomedical materials leader supplying bioresorbable polymers, coatings, and drug delivery technologies to medical device manufacturers. Jeff Orosco previously worked at DSM Biomedical; comparable as a Dutch biomaterials partner/incumbent in VIVOLTA's supplier network.

TypeOthers
Description

Dutch supplier of bioresorbable polymers and lactic acid-based materials for medical devices. Strategic partner in the STENTiT regenerative stent consortium; comparable as an enabling materials provider to electrospun implant manufacturers.

TypeEmerging player
Description

French medtech developing programmable tissue adhesives and polymers for tissue reconstruction and drug delivery. Comparable in next-generation polymer-based platforms for cardiovascular and general surgery applications.

TypeBroad incumbent
Description

US-based regenerative medicine company that acquired Polyganics. Broader portfolio of regenerative devices across dural repair, nerve regeneration, and ENT — overlaps with VIVOLTA's neurosurgery and ENT target segments.

TypeDirect peer
Description

UK-based electrospinning specialist offering contract manufacturing and equipment for biomedical applications. Most directly comparable to VIVOLTA's MediSpin and EC-CLI offerings; Jeff Orosco joined VIVOLTA from this company.

TypeEmerging player
Description

Dutch clinical-stage company developing bioabsorbable restorative cardiovascular devices using supramolecular polymers. Comparable in regenerative vascular implant focus and Dutch high-tech medical device ecosystem positioning.

TypeDirect peer
Description

Dutch medical device company developing bioresorbable electrospun regenerative stents. Active VIVOLTA partner (critical limb ischemia program) and overlaps directly on electrospun vascular scaffold technology.

10Mediliant
TypeDirect peer
Description

Swiss medical device CDMO where VIVOLTA CEO Denis Leissing previously served as CEO. Directly comparable as a specialized medical device contract development and manufacturing organization serving implant and combination product clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vivolta

Medical Device Contract Manufacturingvivolta.com

Vivolta firmographics

Firmographics
Name
Vivolta
Legal name
Vivolta B.V.
Website
https://vivolta.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Vivolta industry classification

Industry
Product category
Medical Device Contract Manufacturing
NAICS
Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Medical device manufacturing
  • Electrospinning technology
  • Contract development manufacturing
  • Biomedical contract services
  • Regenerative medical devices

Where Vivolta is headquartered

Location

Headquarters

HQ city
Waalre
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

Vivolta business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing (CDMO): VIVOLTA provides full-suite CDMO services spanning from concept development to commercial manufacturing. Services include feasibility testing, product & process development, process validation & scale-up, and clinical & commercial manufacturing. The company consolidates clients' supply chains into a one-stop-shop for electrospun medical products and components, managing raw material vendors and integrating post-processes such as laser cutting, packaging, and labelling.
  2. Electrospinning Equipment Sales: VIVOLTA sells EC-CLI climate-controlled electrospinning R&D platforms to academic research institutes and companies globally. Over 120 IME electrospinning R&D platforms have been sold and distributed across six continents.
  3. Development Services: Concept creation, feasibility testing, and product & process development services for medical device companies developing electrospun products.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Vivolta product offering

Product offering

Core offering

Vivolta is a fully integrated contract development and manufacturing organization (CDMO) that develops, validates, and manufactures electrospun medical products and components on its proprietary MediSpin™ automated production platform. Its services span concept creation, feasibility testing, product and process development, process validation and scale-up, and clinical and commercial manufacturing for cardiovascular, orthopaedic, wound care, drug delivery, dental, neurosurgery, and ENT applications. The company also sells EC-CLI climate-controlled electrospinning R&D systems to academic and corporate research users worldwide.

Product overview

VIVOLTA is a fully integrated contract development and manufacturing organization (CDMO) specializing in electrospinning for the medical device industry. The company offers the MediSpin™ Platform as its core production technology—the world's first fully automated medical electrospinning production system—and the EC-CLI Platform for R&D purposes. VIVOLTA provides a full suite of CDMO services spanning from concept development to commercial manufacturing, including add-on modules for the EC-CLI such as the EM-ASM Anti-Statics Module, EM-GSM Gas Shield Module, EM-TMM Thickness Measurement Module, EM-RDC Rotating Drum Collector, and EM-CAX Coaxial Nozzle. The company manufactures various electrospun medical products and components for applications including cardiovascular, orthopaedic, wound healing, and drug delivery.

Differentiator

Problem solved

Functional benefit

Products and services

  • MediSpin™ Production Platform The world's first and only fully automated, scalable medical electrospinning production platform, used by Vivolta to manufacture electrospun medical products and components at commercial scale with real-time sensor-controlled parameters and 100% in-line quality verification.
  • EC-CLI Electrospinning R&D System Climate-controlled electrospinning R&D system with ±0.5°C and ±2% RH accuracy and modular plug-and-play add-ons, sold to academic and corporate research users globally for reproducible prototyping and process development.
  • Contract Development Services Full-service CDMO development offerings including concept creation, feasibility testing, and product and process development for medical device companies targeting electrospun implants and regenerative products.
  • Contract Manufacturing Services Clinical and commercial production services for electrospun medical products including process validation, scale-up, supply chain management, and integration of post-processes such as laser cutting, packaging, and labelling.
  • SimplySilk® Membrane Manufacturing Exclusive contract manufacturing of Fibrothelium's CE-marked Class III SimplySilk® resorbable barrier membrane for guided bone regeneration in dental implants, periodontal procedures, and cranio-maxillo-facial surgery, produced on MediSpin™ at commercial scale.
  • Neurochase Micro-Catheter Manufacturing Exclusive component manufacturing of Neurochase's electrospun micro-catheters for delivering advanced CNS therapies to the brain via convection enhanced delivery (CED), using MediSpin™ at scale.

Quantifiable outcome

  • Fiber diameter deviation below 5% year-round with climate-sealed chambers holding ±0.5°C and ±1% relative humidity
  • +4 more outcomes

Companies that use Vivolta

Customer profile

Named customers2 records

Segments8 records

Ideal customer profiles2 records

Vivolta technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Vivolta partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and strategic.

  • Fibrothelium GmbHcoreStrategic or Co-development Partner · 7 August 2025VIVOLTA signed a long-term partnership with Fibrothelium, a specialist in silk protein biomaterials, to exclusively manufacture electrospun components for Fibrothelium's SimplySilk® membrane - an advanced electrospun silk membrane for guided bone regeneration (GBR) in oral surgery. VIVOLTA leverages its fully automated MediSpin™ technology to produce the electrospun membranes at commercial scale while ensuring consistent quality and regulatory compliance. SimplySilk® membrane is a CE-marked Class III medical device commercially available in Europe, with FDA submission targeted for 2027.
  • NeurochasecoreStrategic or Co-development Partner · 14 November 2024VIVOLTA signed a long-term partnership with Neurochase, a CNS delivery platform specialist, to manufacture electrospun micro-catheters for delivering advanced therapies to the brain via Convection Enhanced Delivery (CED). VIVOLTA first partnered with Neurochase in 2022 and has worked as part of Neurochase's R&D team, bringing material science and application development expertise. VIVOLTA will be Neurochase's exclusive component manufacturer based on its ability to manufacture electrospun medical products at scale using MediSpin™. Neurochase plans clinical trials in 2025.
  • AvelostrategicStrategic or Co-development Partner · 26 October 2023VIVOLTA, Avelo, and BLINK consortium awarded €1.5M Eurostars grant (BreathCounts project) to develop a diagnostic system for lower respiratory tract infections. VIVOLTA contributes electrospun filter technology for a disposable breath collection device. The project aims for market launch in 2027 with the world's first breath-based system for fast, accurate diagnosis of LRTIs.
  • BLINKstrategicStrategic or Co-development Partner · 26 October 2023VIVOLTA, Avelo, and BLINK consortium awarded €1.5M Eurostars grant (BreathCounts project) to develop diagnostic system for lower respiratory tract infections using breath analysis technology combined with VIVOLTA's electrospun filter.
  • Dutch Research Council (NWO)strategicStrategic or Co-development Partner · 20 December 2022VIVOLTA awarded NWO grant along with collaborators Delft University, DSM, and Meatable for Project SUSTAINER investigating feasibility of electrospinning natural and synthetic structural proteins for sustainable food and biomedical applications. Grant of €1 million as part of NWO's Open Technology Programme, running for five years.
  • STENTiTstrategicStrategic or Co-development Partner · 8 July 2022VIVOLTA, STENTiT, and Corbion announced collaboration to develop an electrospun, regenerative stent for clinical use, initially focused on treatment of patients suffering from critical limb ischemia. The consortium aims to manufacture batches of clinical-grade stents together. The regenerative stent uses bioresorbable nanofibers that allow influx of circulating blood cells, triggering natural healing response for vascular regeneration, then safely resorbs over time.
  • CorbionstrategicStrategic or Co-development Partner · 8 July 2022VIVOLTA, STENTiT, and Corbion collaboration to develop regenerative stent for critical limb ischemia treatment. Corbion provides bioresorbable materials expertise as part of the Dutch Smart BioMaterials Consortium (SBMC).

Scale indicators10 records

Recent moves2 records

Vivolta competitors and assessment

Company assessment

Direct peers

  • Polyganics: Dutch regenerative medicine company developing bioresorbable medical devices including dural and nerve repair products. Comparable electrospun/biopolymer device focus; Rudy Mareel (VIVOLTA Chairman) previously led Polyganics to its Regenity acquisition.
  • The Electrospinning Company: UK-based electrospinning specialist offering contract manufacturing and equipment for biomedical applications. Most directly comparable to VIVOLTA's MediSpin and EC-CLI offerings; Jeff Orosco joined VIVOLTA from this company.
  • STENTiT: Dutch medical device company developing bioresorbable electrospun regenerative stents. Active VIVOLTA partner (critical limb ischemia program) and overlaps directly on electrospun vascular scaffold technology.
  • Mediliant: Swiss medical device CDMO where VIVOLTA CEO Denis Leissing previously served as CEO. Directly comparable as a specialized medical device contract development and manufacturing organization serving implant and combination product clients.

Emerging players

  • CollPlant Biotechnologies: Israel-based regenerative medicine company using plant-derived recombinant human collagen for tissue repair and 3D bioprinting. Comparable in ECM-mimicking biomaterials for soft tissue, orthopaedic, and wound healing applications.
  • Tissium: French medtech developing programmable tissue adhesives and polymers for tissue reconstruction and drug delivery. Comparable in next-generation polymer-based platforms for cardiovascular and general surgery applications.
  • Xeltis: Dutch clinical-stage company developing bioabsorbable restorative cardiovascular devices using supramolecular polymers. Comparable in regenerative vascular implant focus and Dutch high-tech medical device ecosystem positioning.

Broad incumbents

  • DSM Biomedical: Dutch biomedical materials leader supplying bioresorbable polymers, coatings, and drug delivery technologies to medical device manufacturers. Jeff Orosco previously worked at DSM Biomedical; comparable as a Dutch biomaterials partner/incumbent in VIVOLTA's supplier network.
  • Regenity Biosciences: US-based regenerative medicine company that acquired Polyganics. Broader portfolio of regenerative devices across dural repair, nerve regeneration, and ENT — overlaps with VIVOLTA's neurosurgery and ENT target segments.

Others

  • Corbion: Dutch supplier of bioresorbable polymers and lactic acid-based materials for medical devices. Strategic partner in the STENTiT regenerative stent consortium; comparable as an enabling materials provider to electrospun implant manufacturers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights7 records

Customer concentration

Vivolta social profiles

Digital presence

Vivolta compliance and trust

Trust signal

Compliance1 record

Vivolta financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vivolta leadership team

Management profile

Number of profiles

Profiles13 records

Vivolta funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vivolta M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivolta

What does Vivolta do?

Vivolta is a fully integrated contract development and manufacturing organization (CDMO) that develops, validates, and manufactures electrospun medical products and components on its proprietary MediSpin™ automated production platform. Its services span concept creation, feasibility testing, product and process development, process validation and scale-up, and clinical and commercial manufacturing for cardiovascular, orthopaedic, wound care, drug delivery, dental, neurosurgery, and ENT applications. The company also sells EC-CLI climate-controlled electrospinning R&D systems to academic and corporate research users worldwide.

Is Vivolta a public or private company?

Vivolta is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vivolta founded?

Vivolta was founded in 2008. It employs 11 to 50 people.

Where is Vivolta based?

Vivolta is headquartered in Waalre, Netherlands, in the Europe region.

How does Vivolta make money?

Three revenue lines are on record. Contract Development and Manufacturing (CDMO) is the primary driver. The others are electrospinning Equipment Sales and development Services.

Who are Vivolta's main competitors?

Direct peers on record are Polyganics, The Electrospinning Company, STENTiT and Mediliant. Emerging players are CollPlant Biotechnologies, Tissium and Xeltis. Broad incumbents are DSM Biomedical and Regenity Biosciences. Corbion is listed as an others.

Does Vivolta have an API?

No public API is recorded for Vivolta.

What industry is Vivolta in?

Vivolta's product category is Medical Device Contract Manufacturing. Its primary akta.pro industry code is HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireVIVOLTA expands regenerative implant manufacturing capability with dedicated facilityVIVOLTA, a specialist in electrospun medical implant manufacturing, has signed a long-term agreement for a dedicated production facility at High Tech Campus Eindhoven in the Netherlands. The new site will include 400 square meters of ISO Class 7-qualified cleanrooms and MediSpin™ production lines for high-throughput medical-grade electrospinning, adding commercial manufacturing capacity to VIVOLTA's existing ISO 13485-certified facility. The expansion reflects sustained commercial growth and increasing customer demand for industrial-scale manufacturing of regenerative medical implants across cardiovascular, wound care, orthopaedics, and soft tissue repair applications.MorningstarVivolta B.V. Accelerates Growth Strategy With Appointment of Didier Deltort to Supervisory BoardVivolta B.V. appointed Didier Deltort to its Supervisory Board, bringing over 30 years of healthcare technology leadership. He previously held senior roles at GE Healthcare, Boston Scientific, Zimmer Biomet, and HP Inc. The appointment aims to support Vivolta's growth in electrospinning solutions for medical devices.YahooVivolta B.V. Accelerates Growth Strategy With Appointment of Didier Deltort to Supervisory BoardVivolta B.V. appointed Didier Deltort to its Supervisory Board, bringing over 30 years of healthcare technology leadership. He previously held senior roles at GE Healthcare, Boston Scientific, Zimmer Biomet, and HP Inc. The appointment aims to support Vivolta's growth in electrospinning medical solutions.Business Wire BlogVivolta B.V. Accelerates Growth Strategy With Appointment of Didier Deltort to Supervisory BoardVivolta B.V. appointed Didier Deltort to its Supervisory Board, citing his medical device experience. Deltort brings over 30 years in healthcare technology, including senior roles at GE Healthcare, Boston Scientific, Zimmer Biomet, and HP. He will support Vivolta's co-development of electrospun medical products with Medtech partners.BioSpaceAvelo, VIVOLTA, and BLINK Win €1.5M Eurostars Grant to Develop New Solution for Diagnosing Lower Respiratory Tract InfectionsAvelo, VIVOLTA, and BLINK have secured a €1.5M Eurostars grant to develop the BreathCounts project, a new non-invasive diagnostic system for lower respiratory tract infections using patient breath samples. The consortium aims to launch this market solution by 2027, enabling clinicians to distinguish between viral and bacterial infections within 30 minutes to combat antimicrobial resistance.Business Wire BlogAvelo, VIVOLTA, and BLINK Win €1.5M Eurostars Grant to Develop New Solution for Diagnosing Lower Respiratory Tract InfectionsAvelo, VIVOLTA, and BLINK have secured a €1.5 million Eurostars grant to develop the BreathCounts consortium's non-invasive diagnostic system for lower respiratory tract infections using patient breath samples. The two-year project aims to create a disposable breath collection device and a high-throughput molecular assay capable of distinguishing viral from bacterial infections within 30 minutes, with a market launch targeted for 2027. This collaboration seeks to address the global health challenge of antimicrobial resistance by enabling faster, more accurate diagnosis at the point-of-need.Business Wire BlogVIVOLTA Raises €7 Million Financing to Further Execute Its Growth Strategy as Medical Electrospinning CDMOVIVOLTA raised €7 million in a funding round with existing shareholders and the Dutch government's NXTGEN HIGHTECH growth fund. The proceeds will support expansion of its ISO class 7 production area and the MediSpinTM platform for manufacturing electrospun medical products. The company plans to focus on cardiovascular, soft tissue, orthopedic, and drug delivery applications.FinSMEsVivolta Raises €7M in FundingVivolta, a Dutch manufacturer of electrospun medical products, has raised €7M in funding from existing shareholders and the Dutch government’s NXTGEN HIGHTECH growth fund. The company plans to use the capital to expand its client-centric services and proprietary MediSpin production platform across various therapeutic areas.VivoltaVIVOLTA secures €7 million in new fundingVIVOLTA secured €7 million in a new funding round with participation from existing shareholders and the Dutch government’s NXTGEN HIGHTECH growth fund. The proceeds will support the expansion of its ISO class 7 production area and enhance its proprietary MediSpin platform for high-throughput manufacturing of medical devices. This investment prepares the company for the clinical and commercial launch of client projects scheduled over the next three years.PR NewswireIME Medical Electrospinning announces name change to VIVOLTAVIVOLTA, formerly IME Medical Electrospinning, announced its corporate name change, completing a transformation from a High-Tech equipment builder into a MedTech company focused on nanofiber-based medical devices, tissue engineering, and drug delivery solutions. The company highlighted major achievements including building a clinical-grade facility with GLP Laboratory and cleanrooms, launching its MediSpin® technology platform for large-scale production, obtaining ISO 13485 certification, and co-authoring the first ASTM standard for fiber-based medical scaffolds. Looking ahead, VIVOLTA aims to bring next-generation Women's Health solutions to market in collaboration with MedTech and Pharma partners.